Claims for Patent: 10,046,081

Summary for Patent: 10,046,081

Title:	Electrospun dextran fibers and devices formed therefrom
Abstract:	The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.
Inventor(s):	Bowlin; Gary (Mechanicsville, VA), Simpson; David (Mechanicsville, VA), Bowman; James (Richmond, VA), Rothwell; Stephen (Richmond, VA)
Assignee:	The Henry M Jackson Foundation for the Advancement of Military Medicine, Inc. (Rockville, MD) Virginia Commonwealth University (Richmond, VA)
Application Number:	14/445,566
Patent Claims:	1. A hemostatic product comprising: a first hemostatic layer comprising a first dextran support consisting of electrospun dextran fibers and thrombin placed on the first dextran support, and a second hemostatic layer comprising a second dextran support consisting of electrospun dextran fibers and fibrinogen placed on the second dextran support, wherein the first and second hemostatic layers are arranged in a stacked configuration to form the hemostatic product so that the thrombin is separate from the fibrinogen. 2. The hemostatic product of claim 1, and further comprising a top dextran support that covers the second hemostatic layer. 3. The hemostatic product of claim 1, wherein the hemostatic product comprises between about 5 and 10 of the first and second hemostatic layers. 4. The hemostatic product of claim 1, wherein the first dextran support has a moisture content of up to 5% by weight and wherein contact between the thrombin and the moisture causes the thrombin to be retained on the first dextran support. 5. The hemostatic product of claim 1, wherein the hemostatic product further comprises a support material selected from the group consisting of gauze, electrospun dextran, polyglycolytic acid polymers, polylactic acid polymers, caprolactone polymers and charged nylon and wherein the first hemostatic layer is adjacent the support material. 6. The hemostatic product of claim 1, wherein the thrombin is human thrombin and wherein the fibrinogen is human fibrinogen. 7. A method of preparing a hemostatic product according to claim 1 comprising: fabricating a first hemostatic layer by placing thrombin on a first dextran support that consists of electrospun dextran fibers; fabricating a second hemostatic layer by placing fibrinogen on a second dextran support that consists of electrospun dextran fibers; and arranging the first and second hemostatic layers in a stacked configuration so that the thrombin is separate from the fibrinogen. 8. The method of claim 7, and further comprising covering the second hemostatic layer with a top dextran support. 9. The method of claim 7, wherein the hemostatic product comprises between about 5 and 10 of the first and second hemostatic layers. 10. The method of claim 7, and further comprising placing the first hemostatic layer on a support material that is selected from the group consisting of gauze, electrospun dextran, polyglycolytic acid polymers, polylactic acid polymers, caprolactone polymers and charged nylon.

Details for Patent 10,046,081

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Omrix Biopharmaceuticals Ltd	EVITHROM	thrombin, topical (human)	Solution	125247	08/27/2007		2028-04-11
Omrix Biopharmaceuticals Ltd	EVITHROM	thrombin, topical (human)	For Injection	125247	09/17/2009		2028-04-11
Csl Behring Gmbh	RIASTAP	fibrinogen concentrate (human)	For Injection	125317	01/16/2009		2028-04-11
Octapharma Pharmazeutika Produktionsges.m.b.h.	FIBRYGA, FIBRYNA	fibrinogen (human)	For Injection	125612	06/07/2017		2028-04-11